Phaseline

Targets › AGXT

AGXT (Alanine--glyoxylate aminotransferase): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Genitourinary, Metabolic and endocrine; next expected readout Aug 2027.

Peroxisomal aminotransferase that catalyzes the transamination of glyoxylate to glycine and contributes to the glyoxylate detoxification. Also catalyzes the transamination between L-serine and pyruvate and contributes to gluconeogenesis from the L-serine metabolism. (UniProt, P21549)

Open in Phaseline: the race on AGXT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
YolTech TherapeuticsYOLT-203
Gene editing therapy for alanine-glyoxylate aminotransferase (AGXT) deficiency
AGXTPhase 2Primary Hyperoxaluria Type 1Aug 2027
Arbor BiotechnologiesABO-101
Gene therapy delivering a functional copy of the AGXT gene to hepatocytes
AGXTPhase 1Primary Hyperoxaluria Type 1 (PH1)Mar 2029

Conditions

Primary Hyperoxaluria Type 1 (2) Primary Hyperoxaluria Type 1 (PH1) (1)

Modalities

other (1), small molecule (1)

Companies

YolTech Therapeutics (1) Arbor Biotechnologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.